Showing results (1441-1450 of 1,518) with videos related to
Sort By:
Pageof 152
The New England Journal of Medicine|April 17, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenMatthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, et al.Lancet (London, England)|June 17, 2014
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialEdward B Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 24, 2025
Brief Report: Post Hoc Validation of Platinum Ineligibility in NSCLC From the Phase III IPSOS StudySolange Peters, Christian Schulz, Martin Reck, et al.European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.Eclinicalmedicine|September 19, 2025
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysisSara Oresti, Fabio Salomone, Antonio Nuccio, et al.Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|December 3, 2025
Demonstration of a Si<sub>3</sub>N<sub>4</sub> Microring Resonator-Based Aptasensor for Human Urokinase-type Plasminogen Activator (uPA) Detection in Point-of-Care Diagnostics<sup></sup>Jakob Reck, Klara Mihov, Tim-Henry Jakob, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerDavid R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.The New England Journal of Medicine|June 2, 2015
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerJulie Brahmer, Karen L Reckamp, Paul Baas, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2022
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227Julie R Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, et al.The Lancet. Respiratory Medicine|May 20, 2019
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trialGiorgio V Scagliotti, Rabab Gaafar, Anna K Nowak, et al.Pageof 152